Article
Radiology, Nuclear Medicine & Medical Imaging
Lamiaa Zidan, Amir Iravani, Kira Oleinikov, Simona Ben-Haim, David J. Gross, Amichay Meirovitz, Ophra Maimon, Tim Akhurst, Michael Michael, Rodney J. Hicks, Simona Grozinsky-Glasberg, Grace Kong
Summary: This study retrospectively assessed the efficacy and safety of Lu-177-DOTATATE in treating lung NETs with high SSR expression. The results showed that Lu-177-DOTATATE had a good disease control rate and promising PFS and OS.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Oncology
Matthew H. Kulke, Hagen F. Kennecke, Kris Murali, Vijay N. Joish
Summary: The study demonstrates that patients treated with TE in a real-world setting experienced significant, clinically meaningful improvements in CS symptoms. Most patients reported over 30% reduction in daily bowel movements frequency after 3 months of TE treatment, and they also reported improvements in other symptoms.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Medicine, General & Internal
Daniel J. Cuthbertson, Rebecca Shankland, Raj Srirajaskanthan
Summary: Neuroendocrine tumors (NETs) are a diverse group of tumors with various primary sites, functional statuses, and degrees of aggressiveness. The most common sites are the lung, small bowel, pancreas, and appendix. Diagnosis relies on biochemical markers, imaging techniques, and functional imaging. Treatment options range from surgery to disease stabilization approaches, including somatostatin analogues and various therapies. Despite potential complications, NETs have reasonable 5- and 10-year survival rates.
Review
Endocrinology & Metabolism
Yuheng Hu, Zeng Ye, Fei Wang, Yi Qin, Xiaowu Xu, Xianjun Yu, Shunrong Ji
Summary: SSTRs have significant clinical significance in pNETs, serving as important targets for diagnosis and treatment, but further research is needed.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Elisa Lenotti, Andrea Alberti, Francesca Spada, Vito Amoroso, Patrick Maisonneuve, Salvatore Grisanti, Alice Baggi, Susanna Bianchi, Nicola Fazio, Alfredo Berruti
Summary: This study retrospectively evaluated the outcomes of patients with metastatic lung NET treated with first line SSAs in two Italian reference Institutions from 2014 to 2019. The results showed that the long PFS and OS obtained suggest that SSAs could be effective as a first line approach in managing patients with progressive, metastatic pulmonary NET.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Review
Oncology
Yasushi Ichikawa, Noritoshi Kobayashi, Shoko Takano, Ikuma Kato, Keigo Endo, Tomio Inoue
Summary: Theranostics combines therapy and diagnosis in a single chemical entity, with somatostatin receptor scintigraphy and peptide receptor radionuclide therapy being effective methods for neuroendocrine tumors. In Japan, the regulation of radiopharmaceuticals under a complex law system has led to significant drug lag, raising public concerns.
Article
Oncology
Sheila D. Rustgi, Aaron Oh, Jeong Yun Yang, Dasol Kang, Edward Wolin, Chung Y. Kong, Chin Hur, Michelle K. Kim
Summary: The study shows that initiating SSAs at the time of presentation for patients with metastatic GEP-NETs is not cost-effective. Further clinical studies are needed to determine the optimal timing for initiating these drugs.
Review
Biology
Leonidas N. Diamantopoulos, Markos Kalligeros, Thorvardur R. Halfdanarson, Nikolaos Diamantis, Christos Toumpanakis
Summary: There are various systemic combination regimens being investigated for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This review provides an overview of the clinical trials and prospective studies on combination treatments. Results show a wide range of efficacy in reported combinations, and only a few phase 3 trials have shown practice-changing results. Peptide receptor radionuclide therapy (PRRT)-based combinations and anti-vascular endothelial growth factor (VEGF) agent combinations with standard chemotherapy have shown promising results, while immune-checkpoint inhibitor-based combinations have limited applicability.
Review
Oncology
Blandine Jelli, Mariana Brandao, Zita Mekinda, Valerie Durieux, Thierry Berghmans
Summary: This study reviewed the clinical experience of patients with neuroendocrine lung cancer, including carcinoid tumors, large cell neuroendocrine carcinomas, and small-cell carcinomas. The study found that patients with carcinoid tumors who received a carcinoid-like first-line regimen had longer survival compared to those receiving other types of regimens. For large cell neuroendocrine carcinomas, there was no significant difference in survival between SCLC-like and non-small cell lung cancer-like regimens. The systematic review identified different therapeutic options for both types of neuroendocrine lung cancer.
Article
Biochemistry & Molecular Biology
Maria Isabel del Olmo-Garcia, Stefan Prado-Wohlwend, Alexia Andres, Jose M. Soriano, Pilar Bello, Juan Francisco Merino-Torres
Summary: Neuroendocrine neoplasms (NENs) are heterogeneous tumors arising from neuroendocrine cells, many of which overexpress somatostatin receptors (SSTR). As a result, somatostatin and SSTR are important subjects of research for potential biomarkers and treatment options, including the use of somatostatin antagonists in the future.
Review
Oncology
Giuseppe Fanciulli, Roberta Modica, Anna La Salvia, Federica Campolo, Tullio Florio, Nevena Mikovic, Alice Plebani, Valentina Di Vito, Annamaria Colao, Antongiulio Faggiano
Summary: Neuroendocrine neoplasms (NENs) are a group of tumors with diverse clinical presentations and prognoses. Surgery is the most effective treatment, but NENs are often diagnosed at a locally advanced or metastatic stage, requiring additional therapeutic approaches. Chimeric antigen receptor T cells (CAR-T) have shown promising therapeutic effects in NENs, with ongoing clinical trials set to define their role in aggressive cases.
Article
Gastroenterology & Hepatology
Noritoshi Kobayashi, Damian Wild, Felix Kaul, Takeshi Shimamura, Shoko Takano, Yuma Takeda, Naoki Okubo, Akihiro Suzuki, Motohiko Tokuhisa, Yasushi Ichikawa
Summary: PRRT is an effective and safe treatment option for Japanese patients with advanced NETs. The combination treatment showed comparable efficacy to single-agent therapy in this study.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES
(2021)
Article
Oncology
B. Kiesewetter, P. Mazal, E. Kretschmer-Chott, M. E. Mayerhoefer, M. Raderer
Summary: This study retrospectively analyzed the use of somatostatin analogues (SSAs) in pulmonary neuroendocrine tumors (NETs) in general practice in Austria. The results showed that only few patients had undergone somatostatin receptor (SSTR) testing before referral, and there was discordance in SSTR expression between imaging and histological assessment.
Review
Oncology
Teresa Alonso-Gordoa, Ray Manneh, Enrique Grande, Javier Molina-Cerrillo
Summary: Neuroendocrine tumors (NET) are a complex and heterogeneous group of malignancies, with over one-third of patients diagnosed at an advanced stage. Somatostatin analogs (SSA) are the cornerstone in treating advanced well-differentiated NET, but many patients eventually develop resistance to this treatment. Increasing the SSA dose may help control symptoms and tumor growth in some cases, but there are still unanswered questions about the optimal dose, frequency, and patient selection for high-dose SSA use.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2022)
Review
Oncology
Thorvardur R. Halfdanarson, Nadine Mallak, Scott Paulson, Chandrikha Chandrasekharan, Mona Natwa, Ayse Tuba Kendi, Hagen F. Kennecke
Summary: This article discusses the best practices in radioligand therapy for GEP-NETs patients, including imaging, clinical biochemistry, and tumor assessment criteria. Effective monitoring and surveillance measures are crucial for personalized clinical decision-making in individual clinical circumstances.